Personalized Autologous Transplant for Multiple Myeloma

This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and w

Trial Details

NCT ID
NCT04483206
Phase
PHASE1
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Autologous Hematopoietic Stem Cell Transplantation
  • Melphalan
  • Questionnaire Administration
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Patient must have the clinical diagnosis of a plasma cell neoplasm requiring treatment per the treating physician using the International Myeloma W…
  • If enrolling in phase A of this protocol, the patient
  • must have received 2+ lines of therapy as defined by the IMWG; and
  • Must have estimated glomerular filtration rate (eGFR) by Cockcroft-Gault \> 40 mL/min; and

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →